Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: PR Newswire
AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could be used in two ways, firstly to increase specificity in Volition's current assays by removing the background signal and secondly, as an enabling technology in sequencing-based liquid biopsies by enriching nucleosomes of cancer origin from the blood.Dr. Mark Eccleston, one of the founding Scientists and the Business Development Director at Volition commented, "I am extremely excited that this enabling technology could bridge the gap between Volition's epigenetic profiling approach to early detection and those sequencing approaches that have so far been limited to personalized treatment selection. The recent results could impact the entire sector and highlight Volition as a leader in the field of
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- Volition Sponsors Symposium at Veterinary Meeting and ExpoPR Newswire
- VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.MarketBeat
- VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]Yahoo! Finance
- VolitionRx Secures $2.0 Million in FundingPR Newswire
- VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in CatsPR Newswire
VNRX
Earnings
- 11/13/25 - Miss
VNRX
Sec Filings
- 1/8/26 - Form 8-K
- 12/11/25 - Form 8-K
- 11/17/25 - Form 4
- VNRX's page on the SEC website